As a result, HSP90 may be a promising therapeutic target, and several clinical trials are currently underway to assess the efficacy of HSP90 inhibitors alone or in combination with other drugs in the treatment of various types of cancer (Eiseman et al., 2005; Yuno et al., 2018). The gene discussed is HSP90AA1; the disease is cancer.